Skip to content
University of Colorado Anschutz Medical Campus CU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 

Tools & Resources

  • Events Calendar
  • Newsroom
  • Strauss Health Sciences Library
  • Department A-Z Directory
  • Campus Directory
  • Leadership
  • Faculty & Staff Resources
  • Supporter & Alumni Resources
  • Student Resources
  • Campus Map
  • University Policies
  • Give Now

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU System
  • CU Online

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

Division of Medical Oncology

School of Medicine

  • Home
  • Leadership
    • Division Head | Wells Messersmith, MD, FACP
    • Deputy Division Head | Virginia Borges, MD, MMSc
  • Research
  • Cancer Care
    • CARE Clinic
    • Clinical Trials
    • Find a Provider
    • Satellite Locations
  • Education
  • Giving
  • Newsroom
  • Division Resources
  • Division Directory
    • Clinical & Research Faculty
    • Research Services Personnel
    • Administrative Staff
University Quick Links
  • Home
  • Newsroom

Medical Oncology Newsroom

Dr. Kessler Discusses New Testosterone Treatment Options

Jan 19, 2022

Prostate cancer is a hormone dependent cancer, fueled primarily by testosterone which is why oncologists aim to lower testosterone levels in prostate cancer patients.  Although, over time, cancer cells adapt to the lower testosterone levels. 

According to Elizabeth Kessler, MD, there has been emerging clinical research across the country in which very high doses of testosterone are used to combat the adaptation of cells in prostate cancers.  While it may seem counterintuitive, this approach has worked very well. However, there is always a chance that cancer cells will once again outsmart this approach through biological adaptations.  It is for this reason, Dr. Kessler explains, that a switch mechanism has been built into prostate cancer treatment, if there are signs that the high dose testosterone is not working against the cancer, treatment would abruptly switch back to the low testosterone state.  This approach is based off research showing positive response rate in cancers that use the switchback method from a high to low testosterone state. 

Dr. Kessler credits ongoing clinical research at the University of Colorado Anschutz Medical Campus with the ability to provide comprehensive care to cancer patients. "People here really care about what they're doing and are really invested in advancing the science while also taking care of people as individuals" says Dr. Kessler. 


 YOU MAY ALSO LIKE

CU ANSCHUTZ NEWS

CU CANCER CENTER NEWS

DIVISION OF HEMATOLOGY

UCHEALTH TODAY

Medical Oncology (SOM)

CU Anschutz

Research I South

12801 East 17th Avenue

8122

Aurora, CO 80045


720-848-0300

Facebook Twitter
School
  • School of Medicine Home
  • Find a Doctor
  • Find a Researcher
  • Departments
  • Contact Us
  • Donate
  • School Profiles
General
  • Affiliate/Partner Hospitals
  • CU Medicine
  • A-Z Index
  • Directory
  • Map and Parking
  • Webmail
Students
  • Apply Now
  • Alumni
  • Canvas
  • Health Science Library
  • Student Life
  • Colorado Springs Branch
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window